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 Abstract 
  Aims:   In order to determine the prevalence of dementia and mild cognitive impairment (MCI), 
we conducted a population-based study in Japan.  Methods:  Participants included 924 subjects 
aged 65 years or older who resided in the town of Ama-cho. In phase 1 of the study, the Mini-
Mental State Examination and Clinical Dementia Rating were administered for screening pur-
poses. In phase 2 of the study, the subjects who screened positive were further examined by 
neurologists. Dementia and MCI were diagnosed by means of DSM-IV and International Work-
ing Group on MCI criteria, respectively.   Results:   By the prevalence date of June 1, 2010, 24 sub-
jects had deceased or lived outside the town. In total, 723 of the remaining 900 subjects re-
ceived a phase 1 test. In phase 2, 98 subjects were diagnosed with amnestic MCI, 113 subjects 
with non-amnestic MCI, and 82 subjects with dementia. Of the subjects who did not receive the 
phase 1 test, 66 subjects were diagnosed as having dementia according to data from their town 
medical card or the Long-term Care Insurance System. The crude prevalence of amnestic MCI, 
non-amnestic MCI, and dementia were 10.9, 12.6, and 16.4%, respectively.   Conclusion:   Consis-
tent with the striking increase in the number of elderly individuals, we report higher prevalence 
of MCI and dementia in Japan than previously described.    Copyright © 2012 S. Karger AG, Basel 
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 Introduction 
  With the substantial aging of the global population, the number of people with demen-
tia will likely increase. Alzheimer’s Disease International estimated the prevalence of demen-
tia worldwide after conducting an evidence-based Delphi consensus study   [1]  . The Delphi 
study indicated that there were 24.3 million people with dementia in the world in 2001. The 
number of people with dementia is expected to increase to 42.3 million by 2020 and to 81.1 
million by 2040. Life expectancy has been rising, and Japanese women have attained the lon-
gest life expectancy worldwide. Moreover, the speed of aging in the Japanese population is 
projected to be one of the fastest in the world. The identification of subjects at risk for de-
mentia is important for the implementation of potential treatments that may delay or prevent 
cognitive decline. Mild cognitive impairment (MCI) is one of several terms describing a stage 
between normal cognitive changes in aging and dementia and is proposed to be prodromal 
to dementia in some elderly people  [2] . Whereas several epidemiological studies on dementia 
have been conducted in Japan, scarce epidemiological data exist regarding MCI, especially 
in terms of the prevalence of MCI examined directly alongside the prevalence of dementia. 
In order to examine the prevalence of both MCI and dementia, we conducted a population-
based study in Ama-cho, a rural island town in western Japan.
  M e t h o d s  
 Subjects 
  This study was conducted in the municipality of Ama-cho, a rural island town located 
70 km from Yonago City, in the northwestern part of Japan. For about 30 years, board-cer-
tificated neurologists have visited this town to examine dementia patients along with public 
health nurses. To be included in the study, subjects were required to be living and to be le-
gally residing in the town on October 1, 2009. The total population of Ama-cho was 2,434 
(1,197 men and 1,237 women). The number of elderly people aged 65 years or older was 924 
(374 men, mean age  8  SD 77.3  8  7.8 years), which represented 38.0% of the total population.
    The study was approved by the Committee for Medical Research Ethics at Tottori Uni-
versity following the principles outlined in the Declaration of Helsinki. Public health nurses 
supported us in the identification of participants, and all participants provided written in-
formed consent to participate in the study.
  Phase  1  Study 
  In phase 1 of the study, a screening of subjects aged 65 years or older was performed by 
5 clinical psychologists in the town. The screening included an interview with both subjects 
and their families that surveyed cognitive changes, as well as the application of the Mini-
Mental State Examination (MMSE)   [3]   and Clinical Dementia Rating (CDR)   [4]  . Subjects 
with an MMSE score under 27 points and/or CDR judged to be 0.5 or more were deemed 
positive.
  Phase  2  Study 
  In phase 2 of the study, the subjects who screened positive in phase 1 were examined to 
confirm or exclude the presence of dementia or MCI and to classify the type of dementia or 
MCI. All subjects in phase 2 were examined by board-certificated neurologists. To confirm 
the diagnosis, neurologists met with the candidates and their family members at home or in 
official day care centers. Assessment of these subjects involved a careful study of the medical 
history, a physical examination, a drug inventory, a neurological examination, and a com-192
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prehensive cognitive evaluation using the Psychogeriatric Assessment Scale (PAS)  [5]  and the 
Logical Memory Test of the Wechsler Memory Scale-Revised (WMS-R)   [6]  .
    Using magnetic resonance imaging (MRI; Philips Gyroscan Intera 1.5 Tesla), we evalu-
ated hippocampal atrophy and cerebrovascular lesions since both are important criteria for 
a diagnosis of dementia.
  Dementia was diagnosed according to the criteria of the Diagnostic and Statistical Man-
ual of Mental Disorders, 4th edition revised (DSM-IV)   [7]  . For patients with dementia, we 
analyzed dementia-related disorders using the following criteria: (1) Alzheimer’s disease 
(AD) was defined according to the criteria of the National Institute of Neurological and 
Communication Disorders Association  [8] ; (2) vascular dementia (VaD) was defined accord-
ing to the criteria of the National Institute of Neurological Disorders and Stroke and the As-
sociation Internationale pour la Recherche et l’Enseignement en Neurosciences   [9]  ; (3) de-
mentia with Lewy bodies (DLB) was defined according to the consensus guidelines for the 
clinical diagnosis of DLB   [10]  ; (4) Parkinson’s disease dementia (PDD) was defined accord-
ing to the clinical diagnostic criteria for dementia-associated Parkinson’s disease   [11]  ; (5) 
progressive supranuclear palsy (PSP) was defined according to the National Institute of Neu-
rological Disorders and the Society for PSP   [12]  ; (6) frontotemporal lobar degeneration 
(FTLD) was defined according to international criteria   [13]  , and (7) possible idiopathic nor-
mal pressure hydrocephalus (iNPH) was defined according to the clinical guidelines of the 
Japanese Society of Normal Pressure Hydrocephalus  [14] . We excluded cases of cognitive de-
cline secondary to major depression and other mental disorders such as schizophrenia only 
if these were proven to be the main cause for the cognitive decline through a psychiatric in-
terview and the patients’ medical history. The severity of dementia was assessed according 
to a functional assessment staging test (FAST) of AD and classified as follows: FAST4 = mild, 
FAST5 = moderate, and FAST6/7 = severe   [15]  .
    The diagnosis of MCI was given according to the International Working Group on MCI 
criteria   [16]  . The following criteria were obligatory for the diagnosis: (1) the subject or the 
informant had to express some concern about the subject’s cognitive function (cognitive 
complaints); (2) there had to be evidence of a decline in cognitive function on administered 
objective cognitive tasks that were abnormal for the subject’s age and education level; (3) the 
participant had to show no impairment of functional activities of daily living, and (4) the 
subject did not fulfill the DSM-IV dementia criteria. Among the subjects who met the crite-
ria for MCI, subjects having a score 1.5 SD below average on the WMS-R were diagnosed as 
having amnestic MCI   [17]  . The other subjects who did not meet the amnestic MCI criteria 
were diagnosed as having non-amnestic MCI. We examined all the subjects directly in phase 
2 of the study.
  D a t a   A n a l y s i s  
  The prevalence and 95% confidence intervals (CIs) were calculated for all types of de-
mentia as well as for MCI. In order to identify subjects with dementia out of the non-respond-
er pool, we used data from town medical records where the diagnosis of dementia was per-
formed by board-certificated neurologists (K.W.-I., Y.U., K.N.) in our follow-up survey or 
using data from the Long-term Care Insurance System of Japan.
  R e s u l t s  
    Figure 1   shows the general design of the door-to-door two-phase prevalence survey. By 
the prevalence date of June 1, 2010, 24 subjects (2.7%) had deceased or migrated from the 
town. Of the remaining 900 subjects, 723 (80.3%) received a phase 1 test. Compared to phase 193
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1 non-responders, responders were younger (mean 81.7 vs. 76.8 years, respectively) and were 
similar in gender (40.9% male vs. 37.4% male, respectively).
    In total, 332 subjects were classified as having cognitive impairment in phase 1 of the 
study. In phase 2 of the study, 98 subjects were diagnosed with amnestic MCI, 113 subjects 
with non-amnestic MCI, and 82 subjects with dementia. Of the subjects who did not receive 
the phase 1 test, 39 subjects were diagnosed as having dementia according to data from their 
town medical records in our follow-up study, and 27 subjects were diagnosed as having de-
mentia according to the Long-term Care Insurance System. The severity of dementia accord-
  Fig. 1.   General design of the door-to-door two-phase prevalence survey in Ama-cho. The number of sub-
jects involved at each step is shown. 
  Fig. 2.   Severity of dementia subtypes. 194
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ing to FAST is shown in   figure 2  . Seventy-five individuals (50.7%) were at a mild stage, 47 
(31.7%) at a moderate stage, and 26 (17.6%) at a severe stage of dementia. More than half of 
the subjects with AD were at a mild stage; however, more than half of the subjects with VaD 
were at a moderate or severe stage. Forty-five subjects with dementia were instituted in nurs-
ing homes in the town, while 16 subjects with dementia were instituted in nursing homes or 
hospitalized outside the town.
    Prevalence of Dementia and MCI 
    Table 1   shows the number and prevalence of each dementia subtype. Overall, 148 sub-
jects (52 men and 96 women) fulfilled the diagnostic criteria for dementia, yielding a crude 
prevalence for all dementia types of 16.4% (95% CI 14.0–18.9) in elderly individuals aged 65 
years or older. The mean age was 83.1  8  5.9 years (range 72–95) for men and 87.6  8  6.8 years 
(range 68–102) for women. The age-specific prevalence of dementia displayed an exponential 
increase with advancing age for women. However, for men, the prevalence was highest be-
tween 85 and 89 years. The prevalence was higher in men than in women aged less than 90 
years. The age-adjusted prevalence for dementia by the direct method in those aged 65 years 
and older compared with the population structure of Japan in 2008 was estimated to be 11.6% 
according to data from this study.
  Of the 148 demented subjects, 104 (70.3%) were diagnosed with AD (25 men, 79 wom-
en), 23 (15.5%) with VaD (17 men, 6 women), 8 (5.4%) with DLB (3 men, 5 women), 4 (3.4%) 
Table 1. Age- and sex-specific prevalence of dementia
Popula-
tion 
at risk
All types of 
dementia
AD VaD DLB PDD iNPH PSP  Others
n preva-
lence
n preva-
lence
n preva-
lence
n preva-
lence
n preva-
lence
n preva-
lence
n preva-
lence
n preva-
lence
Both genders
65–69 years 156 1 0.6  – – 1 0.6  – – – – – – – – – –
70–74  years 182 3 1.6  – – 2 1.1  – – 1 0.5 – – – – – –
75–79 years 210 23 11.0  15 7.1  6 2.9  – – – – – – – – 2 1.0 
80–84  years 170 32 18.8 22 12.9 4 2.4  3 1.8 – – 1 0.6 – – 2 1.2 
85–89  years 105 45 42.9 32 30.5 5 4.8  2 1.9 2 1.9 2 1.9 1 1.0 1 1.0 
≥90 years 77 44 57.1 35 45.5 5 6.5  3 3.9  1 1.3  – – – – – –
Total 900 148 16.4 104 11.6 23 2.6 8 0.9  4 0.4  3 0.3 1 0.1 5 0.6
Men
65–69 years 72 – – – – – – – – – – – – – – – –
70–74  years 83 2 2.4  – – 1 1.2  – – 1 1.2 – – – – – –
75–79 years 86 14 16.3  6 7.0  6 7.0  – – – – – – – – 2 2.3 
80–84 years 68 12 17.6  6 8.8  3 4.4  1 1.5  – – – – – – 2 2.9 
85–89  years 28 15 53.6  9 32.1 4 14.3  – – – – 1 3.6 1 3.6 – –
≥90 years 25 9 36.0  4 16.0  3 12.0  2 8.0  – – – – – – – –
Total 362 52 14.4 25 6.9  17 4.7  3 0.8 1 0.3 1 0.3 1 0.3 4 1.1
Women
65–69 years 84 1 1.2  – – 1 1.2  – – – – – – – – – –
70–74  years 99 1 1.0  – – 1 1.0  – – – – – – – – – –
75–79 years 124 9 7.3 9 7.3  – –  – – – – – – – – – –
80–84  years 102 20 19.6 16 15.7 1 1.0  2 2.0 – – 1 1.0 – – – –
85–89  years 77 30 39.0 23 29.9 1 1.3  2 2.6 2 2.6 1 1.3 – – 1 1.3 
≥90 years 52 35 67.3 31 59.6  2 3.8  1 1.9  1 1.9 – – – – – –
Total 538 96 17.8 79 14.7 6 1.1  5 0.9 3 0.6 2 0.4 – – 1 0.2
Prevalence = Cases/100.195
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with PDD (1 man, 3 women), 3 (2.0%) with iNPH (1 man, 2 women), and 1 (0.7%) with PSP 
(1 man). Five (3.4%) were diagnosed with mixed or other dementias not classifiable (4 men, 
1 woman). The overall crude prevalence was 11.6% (95% CI 9.5–13.6) for AD and 2.6% 
(95% CI 1.5–3.6) for VaD. The prevalence of AD was three times higher in women than in 
men, while that of VaD was almost three times higher in men than in women. The AD/
VaD ratio was 13.2 in women and 1.5 in men. Crude prevalences were 0.89% (95% CI 0.28–
1.5) for DLB and 0.56% (95% CI 0.07–0.10) for PDD. The AD/DLB ratio in both sexes was 
13.0. 
      Table 2   shows the number and prevalence of MCI cases. In total, 211 subjects (88 men 
and 123 women) fulfilled the diagnostic criteria for MCI, yielding a prevalence of 23.4% (95% 
CI 20.7–26.2) in elderly individuals aged 65 years or older. Crude prevalences were 10.9% 
(95% CI 8.9–12.9) for amnestic MCI and 12.6% (95% CI 10.4–14.7) for non-amnestic MCI. 
The mean age of the subjects with amnestic MCI was 78.7   8   7.7 years for men and 78.7   8  
5.5 years for women. The mean age of the subjects with non-amnestic MCI was 74.4   8   6.9 
years for men and 78.1   8   5.7 years for women. Whereas there was no significant difference 
in the mean age of the subjects with amnestic MCI between men and women, the mean age 
of the subjects with non-amnestic MCI was lower for men than women.
Table 2.   Age- and sex-specific prevalence of MCI
Population
at risk
All types of MCI Amnestic MCI N  on-amnestic MCI
n prevalence n prevalence n prevalence
Both genders
65–69 years 156 26 16.7 8 5.1 18 11.5
70–74 years 182 38 20.9 18 9.9 20 11.0
75–79 years 210 56 26.7 23 11.0 33 15.7
80–84 years 170 59 34.7 33 19.4 26 15.3
85–89 years 105 25 23.8 13 12.4 12 11.4
≥90 years 77 7 9.1 3 3.9 4 5.2
Total 900 211 23.4 98 10.9 113 12.6
Men
65–69 years 72 17 23.6 4 5.6 13 18.1
70–74 years 83 20 24.1 9 10.8 11 13.3
75–79 years 86 19 22.1 10 11.6 9 10.5
80–84 years 68 20 29.4 13 19.1 7 10.3
85–89 years 28 7 25.0 4 14.3 3 10.7
≥90 years 25 5 20.0 3 12.0 2 8.0
Total 362 88 24.3 43 11.9 45 12.4
Women
65–69 years 84 9 10.7 4 4.8 5 6.0
70–74 years 99 18 18.2 9 9.1 9 9.1
75–79 years 124 37 29.8 13 10.5 24 19.4
80–84 years 102 39 38.2 20 19.6 19 18.6
85–89 years 77 18 23.4 9 11.7 9 11.7
≥90 years 52 2 3.8 – – 2 3.8
Total 538 123 22.9 55 10.2 68 12.6
Pr  evalence = Cases/100.196
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  Discussion 
  We conducted a population-based study on dementia and MCI in Ama-cho, a rural is-
land town in western Japan. Ama-cho has evidently a stable population in terms of elderly 
population due to very low levels of migration. Three public health nurses working as per-
manent care providers had kept detailed information about the physical and mental health 
of the entire town for about 30 years. Almost all of the subjects with dementia lived in their 
own home or were instituted in a nursing home within the town. Thus, these features proved 
suitable for investigations into the prevalence of dementia.
    We previously reported the crude prevalence of dementia to be 11.0% in elderly indi-
viduals aged 65 years or older   [18]  . In that study, screening for dementia depended upon in-
formation collected by public health nurses in the town. The screening included an interview 
with both subjects and their families and surveyed cognitive changes, psychiatric symptoms, 
personality changes, problem behaviors, activities of daily living, and psychological and 
medical symptoms. Recorded subjects with dementia were limited to people who were actu-
ally living in the town, meaning that people with dementia who were institutionalized in 
nursing homes outside the town or lived with their families outside the town were excluded. 
In comparison, in the present study, the screening of subjects displaying cognitive impair-
ment based on MMSE and CDR by clinical psychologists in a phase 1 study allowed us to 
detect individuals with mild dementia who had not been recognized by public nurses or doc-
tors in the town. This might account for the greater prevalence of dementia reported in this 
study compared to the values presented in our previous study. Further, we examined the state 
of cognitive function in survey non-responders according to data from their town medical 
card or the Long-term Care Insurance System of Japan. We could also extensively examine 
subjects suffering from various stages of cognitive impairment ranging from mild to severe. 
    This study suggests that AD is the most common and VaD is the second most common 
subtype of dementia in elderly individuals. We also examined the prevalence of dementia 
subtypes other than AD and VaD. The proportion of patients with DLB (among patients with 
any type of dementia) was 5.4%, while the proportion of patients with PDD was 2.7%. These 
values are consistent with previous estimates reported in systematic reviews   [19, 20]  . We did 
not discover any patients with FTLD in this study, although a larger number of subjects may 
be needed to examine the exact prevalence of FTLD in the elderly via community-based 
studies.
    Previous reports have demonstrated the prevalence of MCI to be 4.9 and 5.3% in Japa-
nese communities   [21, 23]  . Our estimate of the crude prevalence of MCI (23.4%) was higher 
compared to these previous reports. The non-amnestic type of MCI was included in the con-
struct of MCI in the current study but not in previous studies, and this might account for the 
greater estimated prevalence of MCI. However, the crude prevalence of amnestic MCI (10.6%) 
in the current study is also higher compared to previous reports. Recently, Sasaki et al.   [23]   
reported a prevalence of all types of MCI of 18.9% when using a –1.5 SD cut-off level. Taken 
together with our results, around 20% of elderly people aged 65 years or older might suffer 
from MCI in Japan. In comparison, the prevalence of MCI has also been reported in areas 
outside of Japan. A previous review showed that the prevalence of MCI in the general elder-
ly population (older than 65 years) was between 3.1 and 19% in the United States and Europe 
 [24] . The prevalence of MCI among Koreans aged 65 years or older was estimated to be 24.1% 
(95% CI 21.0–27.2) in a nationwide survey   [25]  . A systematic analysis of 22 studies in China 
described a pooled prevalence of MCI in elderly populations of 12.7% (95% CI 9.7–16.5)   [26]  . 
One of the challenges of studying the prevalence of MCI in population-based studies is that 
the reported prevalence of MCI varies between reports due to different diagnostic criteria as 
well as disparate assessment procedures. Another confound is that up to 44% of subjects with 197
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MCI at their first visit were estimated to return to normal after a year   [24, 27]  . Apart from 
neurodegeneration, numerous factors including vascular risk factors, education, psychiatric 
status, genetic background, use of anticholinergic drugs, and hormonal changes can affect 
cognitive function in elderly populations   [28]  . Recently, the National Institute on Aging-
Alzheimer’s Association workgroup (NIA-AA) and the American Heart Association/Amer-
ican Stroke Association have published a diagnostic recommendation of MCI due to AD  [29]  
and a statement on vascular cognitive impairment   [30]  , respectively. It will be important to 
incorporate these new criteria for MCI in future population-based studies.
    There are some limitations regarding our measurements of MCI prevalence. First, we 
did not conduct cognitive tests in subjects who did not answer the survey. A recent commu-
nity-based study describing a 2.3-fold increase in the prevalence of MCI in delayed respond-
ers compared to quick responders forces us to consider the possibility of undetected MCI in 
our non-responder subjects   [31]  . Therefore, the prevalence of MCI reported in this study 
likely represents a minimum value. Second, we did not perform more extensive tests measur-
ing other cognitive domains aside from memory due to the time limitations for assessing 
community residents, and we classified MCI into only amnestic and non-amnestic types.
    We conducted a door-to-door epidemiological study on the prevalence of mild to severe 
cognitive impairment in a rural island town in western Japan. With the striking increase in 
the elderly population, the number of individuals with dementia or preclinical stages of de-
mentia would appear to be increasing in Japan.
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